Single-stranded DNA aptamer RT1t49 inhibits RT polymerase and RNase H functions of HIV type 1, HIV type 2, and SIVCPZ RTs

AIDS Research and Human Retroviruses

Volumn 23, Issue 5, 2007, Pages 699-708

  Kissel, Jay D ^a   Held, Daniel M ^a,b,c   Hardy, Richard W ^a   Burke, Donald H ^c  

^a INDIANA UNIVERSITY   (United States)

^b SRI INTERNATIONAL   (United States)

^c University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; EFAVIRENZ; NEVIRAPINE; RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; RT1T49; SINGLE STRANDED DNA; SINGLE STRANDED RNA; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ARTICLE; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVITY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; VIRUS MUTATION; VIRUS RESISTANCE;

ANIMALS; APTAMERS, NUCLEOTIDE; DNA, SINGLE-STRANDED; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HIV-2; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS; RIBONUCLEASE H, CALF THYMUS; RNA-DIRECTED DNA POLYMERASE; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 34249864559     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.0262     Document Type: Article

References (59)

1. D'Aquila RT, Schapiro JM, Brun-Vezinet F, et al.: Drug resistance mutations in HIV-1. Top HIV Med 2002;10:21-25.
2. Johnson VA, Brun-Vezinet F. Clotet B, et al.: Drug resistance mutations in HIV-1. Top HIV Med 2003;11:215-221.
3. Johnson VA, Brun-Vezinet F, Clotet B, et al.: Update of the drug resistance mutations in HIV-1: 2004. Top HIV Med 2004;12:119-124.
4. Gurtler LG, Hauser PH, Eberle J, et al.: A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon. J Virol 1994;68:1581-1585.
5. Robertson DL, Anderson JP, Bradac JA, et al.: HIV-1 nomenclature proposal. Science 2000;288:55-56.
6. Simon F, Mauclere P, Roques P, et al.: Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. Nat Med 1998;4:1032-1037.
7. Preston BD, Poiesz BJ, and Loeb LA: Fidelity of HIV-1 reverse transcriptase. Science 1988;242:1168-1171.
8. Roberts JD, Bebenek K, and Kunkel TA: The accuracy of reverse transcriptase from HIV-1. Science 1988;242:1171-1173.
9. Perelson AS, Neumann AU, Markowitz M, Leonard JM, and Ho DD: HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582-1586.
10. Jetzt AE, Yu H, Klarmann GJ, Ron Y, Preston BD, and Dougherty JP: High rate of recombination throughout the human immunodeficiency virus type 1 genome. J Virol 2000;74:1234-1240.
11. Zhuang J, Jetzt AE, Sun G, et al.: Human immunodeficiency virus type 1 recombination: Rate, fidelity, and putative hot spots. J Virol 2002;76:11273-11282.
12. Frost SD, Gunthard HF, Wong JK, Havlir D, Richman DD, and Leigh Brown AJ: Evidence for positive selection driving the evolution of HIV-1 env under potent antiviral therapy. Virology 2001;284:250-258.
13. Wolinsky SM, Korber BT, Neumann AU, et al.: Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 1996;272:537-542.
14. Spence RA, Kati WM, Anderson KS, and Johnson KA: Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 1995;267:988-993.
15. Gonzales MJ, Machekano RN, and Shafer RW: Human immunodeficiency virus type 1 reverse-transcriptase and protease subtypes: Classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population. J Infect Dis 2001;184:998-1006.
16. Gonzales MJ, Wu TD, Taylor J, et al.: Extended spectrum of HIV-I reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS 2003;17:791-799.
17. Loemba H, Brenner B, Parniak MA. et al.: Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. Antimicrob Agents Chemother 2002;46:2087-2094.
18. Grossman Z, Istomin V, Averbuch D, et al.: Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C. AIDS 2004;18:909-915.
19. Brenner B, Turner D. Oliveira M, et al.: A VI06M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2003;17:F1-5.
20. Brenner BG, Oliveira M, Doualla-Bell F, et al.: HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 2006;20:F9-13.
21. Julg B and Goebel FD: HIV genetic diversity: Any implications for drug resistance? Infection 2005;33:299-301.
22. Lal RB, Chakrabarti S, and Yang C: Impact of genetic diversity of HIV-1 on diagnosis, antiretroviral therapy & vaccine development. Indian J Med Res 2005;121:287-314.
23. Wainberg MA: HIV-1 subtype distribution and the problem of drug resistance. AIDS 2004;18(Suppl. 3):S63-68.
24. Quan Y, Brenner BG, Marlink RG, Essex M, Kurimura T, and Wainberg MA: Drug resistance profiles of recombinant reverse transcriptases from human immunodeficiency virus type 1 subtypes A/E, B, and C. AIDS Res Hum Retroviruses 2003;19:743-753.
25. Adje C, Cheingsong R. Roels TH, et al.: High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan. Cote d'lvoire. J Acquir Immune Defic Syndr 2001;26:501-506.
26. Boyer PL, Sarafianos SG, Clark PK, Arnold E, and Hughes SH: Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance? PLoS Pathog 2006;2:e10.
27. Joshi PJ, Fisher TS, and Prasad VR: Anti-HIV inhibitors based on nucleic acids: emergence of aptamers as potent antivirals. Curr Drug Targets Infect Disord 2003;3:383-400.
28. Held DM, Kissel JD, Patterson JT, Nickens DG, and Burke DH: HIV-1 inactivation by nucleic acid aptamers. Front Biosci 2006;11:89-112.
29. Bitko V and Bank S: Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses. BMC Microbiol 2001;1:34.
30. Bitko V, Musiyenko A, Shulyayeva O, and Barik S: Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 2005;11:50-55.
31. Palliser D, Chowdhury D, Wang QY, et al.: An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 2006;439:89-94.
32. Tuerk C and Gold L: Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990;249:505-510.
33. Tuerk C, MacDougal S, and Gold L: RNA pseudoknots that inhibit human immunodeficiency virus type 1 reverse transcriptase. Proc Natl Acad Sci USA 1992;89:6988-6992.
34. Andreola ML, Pileur F, Calmels C, et al.: DNA aptamers selected against the HIV-1 RNase H display in vitro antiviral activity. Biochemistry 2001;40:10087-10094.
35. Burke DH, Scales L, Andrews K, and Gold L: Bent pseudoknots and novel RNA inhibitors of type 1 human immunodeficiency virus (HIV-1) reverse transcriptase. J Mol Biol 1996;264:650-666.
36. Schneider DJ, Feigon J, Hostomsky Z, and Gold L: High-affinity ssDNA inhibitors of the reverse transcriptase of type 1 human immunodeficiency virus. Biochemistry 1995;34:9599-9610.
37. DeStefano JJ and Cristofaro JV: Selection of primer-template sequences that bind human immunodeficiency virus reverse transcriptase with high affinity. Nucleic Acids Res 2006;34:130-139.
38. Somasunderam A, Ferguson MR, Rojo DR, et al.: Combinatorial selection, inhibition, and antiviral activity of DNA thioaptamers targeting the RNase H domain of HIV-1 reverse transcriptase. Biochemistry 2005;44:10388-10395.
39. Hannoush RN, Carriero S, Min KL, and Damha MJ: Selective inhibition of HIV-1 reverse transcriptase (HIV-1 RT) RNase H by small RNA hairpins and dumbbells. Chembiochem 2004;5:527-533.
40. Kensch O, Connolly BA, Steinhoff HJ, McGregor A, Goody RS, and Restle T: HIV-1 reverse transcriptase-pseudoknot RNA aptamer interaction has a binding affinity in the low picomolar range coupled with high specificity. J Biol Chem 2000;275:18271-18278.
41. Chaloin L, Lehmann MJ, Sczakiel G, and Restle T: Endogenous expression of a high-affinity pseudoknot RNA aptamer suppresses replication of HIV-1. Nucleic Acids Res 2002;30:4001-4008.
42. Joshi P and Prasad VR: Potent inhibition of human immunodeficiency virus type 1 replication by template analog reverse transcriptase inhibitors derived by SELEX (systematic evolution of ligands by exponential enrichment). J Virol 2002;76:6545-6557.
43. Ferguson MR, Rojo DR, Somasunderam A, et al.: Delivery of double-stranded DNA thioaptamers into HIV-1 infected cells for antiviral activity. Biochem Biophys Res Commun 2006;344:792-797.
44. Held DM, Kissel JD, Saran D, Michalowski D, and Burke DH: Differential susceptibility of HIV-1 reverse transcriptase to inhibition by RNA aptamers in enzymatic reactions monitoring specific steps during genome replication. J Biol Chem 2006;281:25712-25722.
45. Berenbaum MC: Synergy, additivism and antagonism in immunosuppression. A critical review. Clin Exp Immunol 1977;28:1-18.
46. Lanchy JM, Ehresmann C, Le Grice SF, Ehresmann B, and Marquet R: Binding and kinetic properties of HIV-1 reverse transcriptase markedly differ during initiation and elongation of reverse transcription. EMBO J 1996;15:7178-7187.
47. Basavapathruni A, Bailey CM, and Anderson KS: Defining a molecular mechanism of synergy between nucleoside and nonnucleoside AIDS drugs. J Biol Chem 2004;279:6221-6224.
48. Maga G, Ramunno A, Nacci V. et al.: The stereoselective targeting of a specific enzyme-substrate complex is the molecular mechanism for the synergic inhibition of HIV-1 reverse transcriptase by (R)-(-)-PP0464: A novel generation of nonnucleoside inhibitors. J Biol Chem 2001;276:44653-44662.
49. Cruchaga C, Odriozola L, Andreola M, Tarrago-Litvak L, and Martinez-Irujo JJ: Inhibition of phosphorolysis catalyzed by HIV-1 reverse transcriptase is responsible for the synergy found in combinations of 3′-azido-3′- deoxythymidine with nonnucleoside inhibitors. Biochemistry 2005;44:3535-3546.
50. Chong KT, Pagano PJ, and Hinshaw RR: Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3′-azido-3′-de- oxythymidine or 2′,3′-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro. Antimicrob Agents Chemother 1994;38:288-293.
51. Este JA, Cabrera C, Schols D, et al.: Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (Zintevir). Mol Pharmacol 1998;53:340-345.
52. Jobb G, von Haeseler A, and Strimmer K: TREEFINDER: A powerful graphical analysis environment for molecular phylogenetics. BMC Evol Biol 2004;4:18.
53. Osmanov S, Pattou C, Walker N, Schwardlander B, and Esparza J: Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J Acquir Immune Defic Syndr 2002;29:184-190.
54. Fisher TS, Darden T, and Prasad VR: Mutations proximal to the minor groove-binding track of human immunodeficiency virus type I reverse transcriptase differentially affect utilization of RNA versus DNA as template. J Virol 2003;77:5837-5845.
55. Fisher TS, Joshi P, and Prasad VR: Mutations that confer resistance to template-analog inhibitors of human immunodeficiency virus (HIV) type 1 reverse transcriptase lead to severe defects in HIV replication. J Virol 2002;76:4068-4072.
56. Fisher TS, Joshi P, and Prasad VR: HIV-1 reverse transcriptase mutations that confer decreased in vitro susceptibility to anti-RT DNA aptamer RT1t49 confer cross resistance to other anti-RT aptamers but not to standard RT inhibitors. AIDS Res Ther 2005;2:8.
57. Bebenek K, Beard WA, Darden TA, et al.: A minor groove binding track in reverse transcriptase. Nat Struct Biol 1997;4:194-197.
58. Jaeger J, Restle T, and Steitz TA: The structure of HIV-1 reverse transcriptase complexed with an RNA pseudoknot inhibitor. EMBOJ 1998;17:4535-4542.
59. Jacobo-Molina A, Ding J, Nanni RG, et al.: Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc Natl Acad Sci USA 1993;90:6320-6324.